Evidence map›Paper›PMID 37815132›Full record

ArticleAmerican journal of hematology2023

The FLT3

Sunil K Joshi, Janét Pittsenbarger, Vanessa E Kennedy, Cheryl A C Peretz, Alexander E Perl, Catherine C Smith, Jeffrey W Tyner, Brian J Druker, Elie Traer

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Therapeutic advances of targeting receptor tyrosine kinases in cancer.Signal transduction and targeted therapy · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sunil K JoshiDepartment of Medicine, Stanford University School of Medicine, Stanford, California, USA.ORCID 0000-0003-2798-5762
Janét PittsenbargerKnight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
Vanessa E KennedyDivision of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Cheryl A C PeretzDivision of Hematology and Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, California, USA.
Alexander E PerlDivision of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Catherine C SmithDivision of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Jeffrey W TynerKnight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
Brian J DrukerKnight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
Elie TraerKnight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.

Funding

Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AMLU54CA224019 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Jeffrey Wallace Tyner · 2017 to 2026
$13.9M
Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemiaU01CA271412 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRIAN J DRUKER, Paul D Piehowski · 2022 to 2026
$5.8M
UCSF Paul Calabresi K12 Career Development Program in Clinical OncologyK12CA260225 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BERGSLAND, EMILY K, BIVONA, TREVER G · 2021 to 2025
$2.6M
Defining the stromal landscape that sustains AML drug resistanceF30CA239335 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI JOSHI, SUNIL KUMAR · 2019 to 2022
$187k
NCI NIH HHS F30 CA239335NCI NIH HHS K12 CA260225NCI NIH HHS U01 CA271412NCI NIH HHS U54 CA224019
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsLeukemia, Myeloid, AcuteAniline CompoundsBenzothiazolesfms-Like Tyrosine Kinase 3HumansMutationPhenylurea CompoundsProtein Kinase InhibitorsPyrazinesAniline CompoundsAntineoplastic AgentsBenzothiazolesFLT3 protein, humanfms-Like Tyrosine Kinase 3gilteritinibPhenylurea CompoundsProtein Kinase InhibitorsPyrazinesquizartinib

Identifiers

PMID37815132
PMCPMC10842343

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.